We used mean changes from the time of drug discontinuation to the specified cutoff point of follow-up (week 4, week 8, week 12, week 20, week 26, and week 52) and standard deviations (SDs) extracted from published data when reported
We work with powerful, clinically-proven tools like GLP-1 medications that address weight at its hormonal source
In mouse and human organoids, treatment with SCFA led to an increase in the number of L-cells and glucose-induced GLP-1 secretion
The safest way to reduce side effects is to follow a slow titration schedule, adjust your diet, and use supportive supplements under the guidance of a healthcare provider
Recognized for excellence, we have received accolades like the Times Health Excellence Award in 2024